Background: Success rate of Indonesia Tuberculosis (TB) treatment did not evenly distribute to every province in 2016, although various program had been carried out by Indonesia Government. Bali’s Case Notification Rate (CNR) and Success Rate (SR) of TB also did not reach target in 2017. Successful control of TB can be influenced by community’s level of knowledge and perception about TB. Our research objective was to know communities level of knowledge and perception about TB in Denpasar, Bali. Method: This was cross-sectional research. Our sample was Denpasar communities who visited Puputan Renon Field Car Free Day (CFD) at 25 March 2018. Sample was chosen by consecutive sampling. Results: Our research result was almost (62%) of respondent had poor knowledge about TB and 67% respondent had right perception about TB. Conclusion: We can conclude that Denpasar communities had poor level of knowledge and good perception about TB.
Background: Pleural effusion is caused by various disease, including tuberculosis infection and malignancy. To determine the etiology, immunologic parameters are needed to distinguish tuberculous and malignant pleural effusions, including pleural fluid interleukin-6 (IL-6), neutrophil-lymphocyte ratio (NLR), and monocyte-lymphocyte ratio (MLR).Methods: This was a cross-sectional study, conducted at Sanglah General Hospital in Denpasar from March 2020 to September 2020. Pleural fluid IL-6 and leucocyte differential count were measured from subjects with tuberculous and malignant pleural effusions.Results: There were 22 tuberculous pleural effusion subjects with mean pleural fluid IL-6 9269.017±902.211 pg/ml, median (range) pleural fluid NLR 0.123 (0.044-9.449), and MLR 0.065 (0.044-0.355). There were 31 subjects with malignant pleural effusions, with mean pleural fluid IL-6 8212.146±2022.350 pg/ml, median pleural fluid NLR 0.189 (0.015-2.599), and MLR 0.065 (0.010-0.254). Pleural fluid IL-6 in tuberculous pleural effusions were significantly higher (p=0.014). With a pleural fluid IL-6 cut-off ≥9147.959 pg/ml, sensitivity of 63.6% and specificity of 64.5% were obtained. Pleural fluid NLR and MLR of the two groups were not significantly different (p=0.807 and p=0.116).Conclusions: Pleural fluid IL-6 in tuberculous pleural effusions is higher than malignant pleural effusions, with a cut-off of ≥9147.959 pg/ml, tuberculous pleural effusions can be diagnosed with sensitivity of 63.6% and specificity of 64.5%. There is no difference in pleural fluid NLR and MLR in tuberculous and malignant pleural effusions.
Introduction: Lung cancer found in young age is relatively rare with a percentage of cases only 1.4% of overall lung cancer cases in the world. Case: We reported two cases of lung adenocarcinoma in young women aged less than 30. The first case was lung adenosquamous carcinoma in a 28-year-old woman, a passive smoker, who had a family history of cancer. She had the mutation of epidermal growth factor receptor (EGFR) exon 19 deletion and received 1st generation of tyrosine kinase inhibitor. Since the patient was diagnosed at advanced stage with poor performance status, she died within 2 months after being diagnosed. The second case was lung adenocarcinoma in a 23-year-old woman. The patient was a passive smoker and had a history of cancer in the family. She was diagnosed at an advanced stage but with good performance status. The patient underwent chemotherapy with Pemetrexed-Platinum in 6 cycles and 15 cycles of radiotherapy. Conclusion: Lung cancer at a young age is more common in non-smoking female with the histopathology type adenocarcinoma. Non-specific early symptoms become a problem in the early enforcement of lung cancer at a young age. Many cancer-related issues occur in young cancer patient such as premature death, increased dependence on parents, difficulty in school and work due to medication, and reproductive disturbance.
Background: Omicron (B.1.1.529) is a variant of COVID-19 which is first reported from Gauteng Province, South Africa in November 2021. This variant was considered the fifth variant of concern (VOC) by the world health organization (WHO) due to its much faster transmission but with milder clinical manifestations than other COVID-19 variants.Methods: This retrospective cross-sectional descriptive study was conducted in Sanglah general hospital, Denpasar, Bali in March 2022. Subjects of this study were all patients who were diagnosed with probable COVID-19 Omicron by having a positive S-gene target failure (SGTF) of a reverse transcriptase polymerase chain reaction (RT-PCR) test in Sanglah general hospital from January to February 2022. All subjects must age 18 years old or older. Data on patient characteristics and clinical manifestations were obtained from medical record data and analyzed using statistical package for service solution (SPSS) for windows version 25.Results: A total of 79 probable COVID-19 Omicron patients were analyzed in this study. Most of them were elderly who age more than 65 years old (30.4%), male (50.6%), and work as an entrepreneur (24.1%). The majority of probable COVID-19 Omicron patients were symptomatic (89.9%) with the most common clinical manifestation found was cough (54.9%). Other clinical manifestations found were shortness of breath (50.7%), fever (38.0%), fatigue (21.1%), runny nose (11.3%), sore throat (8.5%), nausea and vomit (2.8%), headache (1.4%), diarrhea (1.4%), and anosmia (1.4%).Conclusions: The clinical manifestations of probable COVID-19 Omicron patients vary but most of them were classified as mild symptoms.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.